Diligence memo · auto-generated · as of July 2, 2026
ProPhase Labs, Inc.
ProPhase Labs, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
ProPhase Labs, Inc. operates in Biotechnology, based in UNIONDALE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ProPhase Labs, Inc. has raised $8.4M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.0M on 2025-07-22.
Most recent recorded round closed around 2025-07-22.
Valuation (modeled)modeled
Provath models ProPhase Labs, Inc. at approximately $8.1M (range $2.2M–$16M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.77× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 61 months.
Last raise 11 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 3.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 53% of Biotechnology peers (4293 compared).
Modeled value ranks above 15% of those peers.
Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.